Table 2.
Comparison of Weighted and Unweighted Patient Groups, Stratified by Use of Secondary Prophylaxis, Showing Variables Included in Propensity Score Model
| Characteristic | Unweighted Sample | Weighted Sample | ||||
|---|---|---|---|---|---|---|
| Did Not Receive SP (n = 50) | Received SP (n = 120) | SMD | Did Not Receive SP (n = 44.37) | Received SP (n = 117.44) | SMD | |
| Age at CMV onset, y, mean ± SD | 52 ± 12 | 53 ± 14 | 0.009 | 53 ± 15 | 53 ± 14 | 0.02 |
| Male sex, no. (%) | 33 (66.0) | 78 (65.0) | 0.021 | 29.3 (66.0) | 77.2 (65.7) | 0.005 |
| White race (vs nonwhite), no. (%) | 34 (68.0) | 93 (77.5) | 0.215 | 29.2 (65.9) | 84.6 (72.1) | 0.133 |
| Previous transplant, no. (%) | 7 (14.0) | 9 (7.5) | 0.211 | 6.0 (13.4) | 12.2 (10.4) | 0.095 |
| Year of CMV disease, mean ± SD | 2005.64 ± 6.53 | 2007.37 ± 4.69 | 0.304 | 2007.78 ± 5.70 | 2007.77 ± 5.06 | 0.001 |
| Transplanted organ, no. (%) | ||||||
| Heart | 17 (34.0) | 35 (29.2) | 0.115 | 13.8 (31.1) | 35.3 (30.1) | 0.175 |
| Liver/liver–kidney | 18 (36.0) | 45 (37.5) | 19.9 (44.8) | 45.2 (38.5) | ||
| Kidney (living unrelated) | 4 (8.0) | 12 (10.0) | 3.4 (7.7) | 11.0 (9.4) | ||
| Kidney (deceased/LR) | 11 (22.0) | 28 (23.3) | 7.3 (16.4) | 26.0 (22.1) | ||
| Receiving hemodialysis during CMV treatment, no. (%) | 2 (4.0) | 3 (2.5) | 0.085 | 1.0 (2.3) | 2.8 (2.4) | 0.009 |
| Recipient CMV seronegative, no. (%) | 27 (54.0) | 64 (53.3) | 0.013 | 20.5 (46.3) | 58.5 (49.8) | 0.071 |
| Antilymphocyte therapy within 1 year of treatment completion, no. (%) | 13 (26.0) | 48 (40.0) | 0.301 | 18.3 (41.2) | 45.5 (38.7) | 0.05 |
| Number of immunosuppressive drugs at treatment completion, mean ± SD | 2.34 (0.66) | 2.35 (0.60) | 0.016 | 2.34 (0.68) | 2.32 (0.60) | 0.04 |
| Steroid-treated rejection within 1 year of treatment completion, no. (%) | 14 (28.0) | 24 (20.0) | 0.188 | 11.0 (24.7) | 24.6 (20.9) | 0.09 |
| Days from transplant to CMV onset, mean ± SD | 777 ± 1462 | 582 ± 1050 | 0.153 | 572 ± 1071 | 599 ± 1056 | 0.025 |
| End organ disease, no. (%) | 34 (68.0) | 86 (71.7) | 0.08 | 30.8 (69.4) | 80.8 (68.8) | 0.012 |
| Peak viral load, mean ± SD | ||||||
| Assay 1, number | 23 (46.0) | 65 (54.2) | 0.164 | 18.4 (41.5) | 59.1 (50.3) | 0.178 |
| Assay 1, value (pg/mL) | 73 ± 181 | 81 ± 189 | 0.047 | 105 ± 235 | 82 ± 195 | 0.106 |
| Assay 2, number | 3 (6.0) | 20 (16.7) | 0.341 | 5.1 (11.4) | 16.2 (13.8) | 0.07 |
| Assay 2, value (copies/mL) | 3069 ± 19852 | 6621 ± 32999 | 0.13 | 2676 ± 15779 | 5631 ± 29796 | 0.124 |
| Assay 3, number | 15 (30.0) | 31 (25.8) | 0.093 | 17.6 (39.7) | 37.5 (31.9) | 0.164 |
| Assay 3, value (copies/mL) | 22544 ± 96136 | 31604 ± 105979 | 0.09 | 21363 ± 78095 | 26970 ± 98092 | 0.063 |
| Treatment duration, days, mean ± SD | 43 ± 36 | 37 ± 28 | 0.179 | 42 ± 30 | 39 ± 29 | 0.086 |
| Treatment type | ||||||
| PO only | 25 (50.0) | 47 (39.2) | 0.353 | 20.8 (47.0) | 53.9 (45.9) | 0.025 |
| IV and PO | 13 (26.0) | 51 (42.5) | 16.6 (37.4) | 44.3 (37.7) | ||
| IV only | 12 (24.0) | 22 (18.3) | 6.9 (15.6) | 19.2 (16.4) | ||
| CMV immune globulin used as part of initial treatment, no. (%) | 6 (12.0) | 11 (9.2) | 0.092 | 2.4 (5.5) | 8.7 (7.4) | 0.078 |
| Chronic kidney disease epidemiology collaboration estimated glomerular filtration rate, mL/min/1.73m2, mean ± SD | 57.1 ± 28.2 | 56.8 ± 24.5 | 0.01 | 58.6 ± 28.1 | 56.6 ± 25.9 | 0.074 |
Abbreviations: CMV, cytomegalovirus; IV, intravenous; LR, living related; PO, oral; SD, standard deviation; SMD, standardized mean difference.